This news release has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising ...
Patent reinforces strategic foundation for lead ADC AKTX-101 and expanding ADC pipeline to new molecules targeting high-value ...
The company is recognized for its innovation, scientific expertise, and customer-centric clinical development model in the ...
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results